1 Min Read
FRANKFURT, March 4 (Reuters) - Bayer AG : * Says Riociguat demonstrated study improvements in 6 min walking distance and
WHO functional class in interim results of phase III Long-term extension
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.